Federico Cappuzzo

15PUBLICATIONS
252CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Liquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jul 15, 2026
Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer.

|Jul 14, 2026
Clinical Significance of EGFR Amplification in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer Receiving First-line Osimertinib.

|May 18, 2026
Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco.

|Apr 10, 2026
First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non-Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 Study.

Jhanelle E Gray, Joel W Neal, Jyoti D Patel

|Dec 03, 2025
Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations.

Tianshi Lu, Habib Hamidi, Mark A Socinski

|Aug 20, 2025
The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial.

Andrea Botticelli, Chiara Cremolini, Simone Scagnoli

Pageof 3

Frequent Collaborators

6 joint publications

Biagio Ricciuti

5 joint publications

Alessandro Di Federico

5 joint publications

Mark Magdi Awad

4 joint publications

Joao Victor Alessi